Drug Courts pp 73-94 | Cite as

The Physical Consequences of Drug and Alcohol Abuse

  • Hitoshi Nakaishi


This chapter discusses the physical consequences of substance abuse, including the representative drugs of alcohol, opioids, cannabis, toluene, cocaine, and lysergic acid diethylamide (LSD). Nicotine is briefly addressed as a legal drug that is not involved in the drug court process but has significant health effects, particularly when used with another drug.


Acute Pancreatitis Chronic Pancreatitis Alcoholic Liver Disease Alcohol Withdrawal Alcoholic Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ringold S, Lynm C, Glass RM. Alcohol abuse and alcoholism. JAMA 2006;295(17):2100.PubMedCrossRefGoogle Scholar
  2. 2.
    Nagel M, Ferbert A. Diseases due to alcoholism. Fortschr Neurol Psychiatry 2005;73(8):470–482.CrossRefGoogle Scholar
  3. 3.
    Al-Sanouri I, Dikin M, Soubani AO. Critical care aspects of alcohol abuse. South Med J 2005;98(3):372–381.PubMedCrossRefGoogle Scholar
  4. 4.
    Ebell MH. Benzodiazepines for alcohol withdrawal. Am Fam Physician 2006;73(7):1191.Google Scholar
  5. 5.
    Petignat PA. The management of the alcohol withdrawal syndrome in the intensive care unit. Rev Med Suisse 2005;1(45):2905–2911.PubMedGoogle Scholar
  6. 6.
    Harper C, Matsumoto I. Ethanol and brain damage. Curr Opin Pharmacol 2005;5(1):73–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Yamamoto M, Ukai W, Tateno M, Saito T. Possible alterations in brain neural network by ethanol. Nihon Arukoru Yakubutsu Igakkai Zasshi 2004;39(1):51–60.PubMedGoogle Scholar
  8. 8.
    Schenker S, Bay MK. Medical problems associated with alcoholism. Adv Intern Med 1998;43:27–78.PubMedGoogle Scholar
  9. 9.
    Hislop WS, Heading RC. Caledonian Society of Gastroenterology. Impact of alcohol related disease and inpatient workload of gastroenterologists in Scotland. Scott Med J 2004;49(2):57–60.PubMedGoogle Scholar
  10. 10.
    Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2005;9(1):135–149.PubMedCrossRefGoogle Scholar
  11. 11.
    Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res 2006;30(4):720–730.PubMedCrossRefGoogle Scholar
  12. 12.
    D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44(1):217–231.PubMedCrossRefGoogle Scholar
  13. 13.
    Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma: an overview. Ann Hepatol 2006;5(1):16–24.PubMedGoogle Scholar
  14. 14.
    Kloppel G. Acute pancreatitis. Semin Diagn Pathol 2004;21(4):221–226.PubMedCrossRefGoogle Scholar
  15. 15.
    Gullo L, Migliori M, Brunetti MA, Manca M. Alcoholic pancreatitis: new insights into an old disease. Curr Gastroenterol Rep 2005;7(2):96–100.PubMedCrossRefGoogle Scholar
  16. 16.
    Kloppel G. Chronic pancreatitis of alcoholic and nonalcoholic origin. Semin Diagn Pathol 2004;21(4):227–236.PubMedCrossRefGoogle Scholar
  17. 17.
    Go VL, Gukovskaya A, Pandol SJ. Alcohol and pancreatic cancer. Alcohol 2005;35(3):205–211.PubMedCrossRefGoogle Scholar
  18. 18.
    Kingsnorth A, O’Reilly D. Acute pancreatitis. BMJ 2006;332(7549):1072–1076.PubMedCrossRefGoogle Scholar
  19. 19.
    Hendriks HF, van Tol A, Alcohol. In von Eckardstein A, ed. Atherosclerosis: Diet and Drugs. New York: Springer; 2005;339–361.CrossRefGoogle Scholar
  20. 20.
    Tykarski A. Resistant hypertension. Blood Press Suppl 2005;2:42–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Russo D, Purohit V, Foudin L, Salin M. Workshop on alcohol use and health disparities 2002: a call to arms. Alcohol 2004;32(1):37–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang X, Li SY, Brown RA, Ren J. Ethanol and acetaldehyde in alcoholic cardiomyopathy: from bad to ugly en route to oxidative stress. Alcohol 2004;32(3):175–186.PubMedCrossRefGoogle Scholar
  23. 23.
    Fernandez-Sola J, Nicolas-Arfelis JM. Gender differences in alcoholic cardiomyopathy. J Gend Specif Med 2002;5(1):41–47.PubMedGoogle Scholar
  24. 24.
    Spies CD, Sander M, Stangl K, Fernandez-Sola J, Preedy VR, Rubin E, Andreasson S, Hanna EZ, Kox WJ. Effects of alcohol on the heart. Curr Opin Crit Care 2001;7(5):337–343.PubMedCrossRefGoogle Scholar
  25. 25.
    Schoppet M, Maisch B. Alcohol and the heart. Herz 2001;26(5):345–352.PubMedCrossRefGoogle Scholar
  26. 26.
    Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias. Chest 2003;123(4):1320.PubMedCrossRefGoogle Scholar
  27. 27.
    Rothman KJ. The proportion of cancer attributable to alcohol consumption. Prev Med 1980;9(2):174–179.PubMedCrossRefGoogle Scholar
  28. 28.
    Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006;7(2):149–156.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferguson LR, Philpott M, Karunasinghe N. Dietary cancer and prevention using antimutagens. Toxicology 2004;198(1–3):147–159.PubMedCrossRefGoogle Scholar
  30. 30.
    Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 2004;63(1):49–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci 2004;9:411–420.PubMedCrossRefGoogle Scholar
  32. 32.
    Leevy CM, Moroianu SA. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005;9(1):67–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Lieber CS. Relationships between nutrition, alcohol use, and liver disease. Alcohol Res Health 2003;27(3):220–231.PubMedGoogle Scholar
  34. 34.
    Fabbri A, Caprio M, Aversa A. Pathology of erection. J Endocrinol Invest 2003;26(3 Suppl):87–90.PubMedGoogle Scholar
  35. 35.
    Clayton AH. Sexual function and dysfunction in women. Psychiatr Clin North Am 2003;26(3):673–682.PubMedCrossRefGoogle Scholar
  36. 36.
    Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290(1):86–97.PubMedCrossRefGoogle Scholar
  37. 37.
    Andrews JO, Tingen MS. The effect of smoking, smoking cessation, and passive smoke exposure on common laboratory values in clinical settings: a review of the evidence. Crit Care Nurs Clin North Am 2006;18(1):63–69.PubMedCrossRefGoogle Scholar
  38. 38.
    Crooks PA, Dwoskin LP. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 1997;54(7):743–753.PubMedCrossRefGoogle Scholar
  39. 39.
    Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol 2005;10(3):219–231.PubMedCrossRefGoogle Scholar
  40. 40.
    Brown RA, Lejuez CW, Kahler CW, Strong DR, Zvolensky MJ. Distress tolerance and early smoking lapse. Clin Psychol Rev 2005;25(6):713–733.PubMedCrossRefGoogle Scholar
  41. 41.
    Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005;80(5):652–656.PubMedCrossRefGoogle Scholar
  42. 42.
    Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncol 2005;23(2):311–323.PubMedCrossRefGoogle Scholar
  43. 43.
    Westmaas JL, Brandon TH. Reducing risk in smokers. Curr Opin Pulm Med 2004;10(4):284–288.PubMedCrossRefGoogle Scholar
  44. 44.
    Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3(10):733–744.PubMedCrossRefGoogle Scholar
  45. 45.
    McCoy GD, Hecht SS, Wynder EL. The roles of tobacco, alcohol, and diet in the etiology of upper alimentary and respiratory tract cancers. Prev Med 1980;9(5):622–629.PubMedCrossRefGoogle Scholar
  46. 46.
    Bartal M. COPD and tobacco smoke. Monaldi Arch Chest Dis 2005;63(4):213–225.PubMedGoogle Scholar
  47. 47.
    Melvin C, Gaffney C. Treating nicotine use and dependence of pregnant and parenting smokers: an update. Nicotine Tobacco Res 2004;(6Suppl 2):S107–S124.CrossRefGoogle Scholar
  48. 48.
    Thomas GA, Rhodes J, Ingram JR. Mechanisms of disease: Nicotine—a review of its actions in the context of gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(11):536–544.PubMedCrossRefGoogle Scholar
  49. 49.
    Templeton K. Secondary osteoporosis. J Am Acad Orthop Surg 2005;13(7):475–486.PubMedGoogle Scholar
  50. 50.
    Sporer KA. Acute heroin overdose. Ann Intern Med 1999;130(7):584–590.PubMedGoogle Scholar
  51. 51.
    Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction 2001;96(8):1113–1125.PubMedCrossRefGoogle Scholar
  52. 52.
    Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(5):849–863.PubMedCrossRefGoogle Scholar
  53. 53.
    Castle DJ, Ames FR. Cannabis and the brain. Aust NZ J Psychiatry 1996;30(2):179–183.CrossRefGoogle Scholar
  54. 54.
    Centers for Disease Control and Prevention. Acute public health consequences of methamphetamine laboratories—16 states, January 2000–June 2004. MMWR Morbid Mortal Wkly Rep 2005;54(14):356–359.Google Scholar
  55. 55.
    Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 2005;81(2):319–330.PubMedCrossRefGoogle Scholar
  56. 56.
    Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002;21(1):21–34.PubMedCrossRefGoogle Scholar
  57. 57.
    Schuster CR, Fischman MW. Amphetamine toxicity: behavioral and neuropathological indexes. Fed Proc 1975;34(9):1845–1851.PubMedGoogle Scholar
  58. 58.
    Worth H, Rawstorne P. Crystallizing the HIV epidemic: methamphetamine, unsafe sex, and gay diseases of the will. Arch Sex Behav 2005;34(5):483–486.PubMedCrossRefGoogle Scholar
  59. 59.
    Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol 2004;63(1):1–12.PubMedGoogle Scholar
  60. 60.
    Nnadi CU, Mimiko OA, McCurtis HL, Cadet JL. Neuropsychiatric effects of cocaine use disorders. J Natl Med Assoc 2005;97(11):1504–1501.PubMedGoogle Scholar
  61. 61.
    Prakash A, Das G. Cocaine and the nervous system. Int J Clin Pharmacol Ther Toxicol 1993;31:575–590.PubMedGoogle Scholar
  62. 62.
    Majewska MD. Cocaine addiction as a neurological disorder: implications for treatment. NIDA Res Monogr 1996;163:1–26.PubMedGoogle Scholar
  63. 63.
    McClelland GT. The effects and management of crack cocaine dependence. Nurs Times 2005;101(29):26–27.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Hitoshi Nakaishi
    • 1
  1. 1.Suginami-Ku, TokyoJapan

Personalised recommendations